Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

25.13
+0.09000.36%
Post-market: 25.180.0500+0.20%19:35 EST
Volume:2.79M
Turnover:70.06M
Market Cap:2.02B
PE:16.41
High:25.60
Open:24.63
Low:24.53
Close:25.04
52wk High:60.91
52wk Low:21.91
Shares:80.39M
Float Shares:78.97M
Volume Ratio:1.19
T/O Rate:3.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.53
EPS(LYR):0.8200
ROE:9.43%
ROA:3.71%
PB:1.41
PE(LYR):30.65

Loading ...

Veracyte Q3 Revenue Beats Estimates on Afirma Growth; Cuts Testing Revenue Outlook

Reuters
·
Nov 05

Veracyte, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Nov 05

Veracyte Q3 Adj. EPS $0.51 Beats $0.41 Estimate, Sales $151.754M Beat $147.439M Estimate

Benzinga Earnings
·
Nov 05

Veracyte Q3 Revenue USD 151.8 Million Vs. IBES Estimate USD 147.4 Million

Reuters
·
Nov 05

Veracyte, Inc.: Announces $100 Mln Share Repurchase Program

THOMSON REUTERS
·
Nov 05

Veracyte Outlook FY Revenue Growth 14-15%

THOMSON REUTERS
·
Nov 05

Veracyte Q3 Adjusted EPS USD 0.51 VS. Ibes Estimate USD 0.41

THOMSON REUTERS
·
Nov 05

Veracyte Announces Third Quarter 2026 Financial Results

GlobeNewswire
·
Nov 05

Veracyte Announces 10 Afirma Thyroid Test Studies for ATA 2026 Meeting

Reuters
·
Nov 02

Veracyte to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Oct 30

Veracyte Director Karin Eastham Reports Sale of Common Shares Worth $742,572.765

Reuters
·
Oct 29

Earning Preview: Veracyte this quarter’s revenue is expected to increase by 17.81%, and institutional views are bullish

Earnings Agent
·
Oct 28

How Investors May Respond To Veracyte (VCYT) Expanded Test Coverage

Simply Wall St.
·
Oct 27

Veracyte’s Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer Study

Reuters
·
Oct 23

Phase Iii Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

THOMSON REUTERS
·
Oct 23

Veracyte Study Shows Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer

Reuters
·
Oct 19

Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

GlobeNewswire
·
Oct 19

Veracyte's Prosigna Breast Cancer Recurrence Test Gets Medicare Coverage

MT Newswires Live
·
Oct 16

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

THOMSON REUTERS
·
Oct 16

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

GlobeNewswire
·
Oct 15